Novel agents for the treatment of HIV-2 infectionKevin Peterson, Sarah Rowland-Jones
Corresponding author name: Kevin Peterson
Corresponding author e-mail: email@example.com
Citation: Antiviral Therapy 2012; 17:435-438
Date published online: 25 January 2012
Many of the antiretrovirals used against HIV-1 are either ineffective or less effective in HIV-2 infection. There is in vitro evidence of the potency of maraviroc and several investigational agents against HIV-2. We conclude that, whilst specific boosted protease inhibitors combined with nucleoside analogues should still be considered the mainstays of HIV-2 treatment, maraviroc, T-1249, TAK-779 and AMD3100, as well as raltegravir, could contribute to regimens for treatment-experienced individuals. Factors bearing on the use and timing of these alternative agents are discussed.